References
- GeertsWHBergqvistDPineoGFPrevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed)Chest2008133381S453S18574271
- JohansonNALachiewiczPFLeibermanJRAAOS Physician Volunteer Work GroupAmerican Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty: summary of recommendationsJ Am Acad Orthop Surg200917318319619264711
- EllisRFStephensMASharpGBEvaluation of a pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapyAm J Hosp Pharm19924923873941554003
- WattsACHowieCRSimpsonAAssessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplastyJ Bone Joint Surg2006881107110
- RoehrigSStraubAPohlmannJDiscovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitorJ Med Chem200548195900590816161994
- PerzbornEKubitzaDMisselwitzFRivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disordersHamostaseologie20072728228917938768
- KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjectsEur J Clin Pharmacol2005611287388016328318
- ErikssonBIBorrisLCFriedmanRJRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplastyN Engl J Med2008358262765277518579811
- KakkarAKBrennerBDahlOEExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialLancet20083729632313918582928
- LassenMRAgenoWBorrisLCRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyN Engl J Med2008358262776278618579812
- TurpieAGLassenMRDavidsonBLRivaroxaban Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty (RECORD4): a randomised trialLancet200937396761673168019411100
- LassenMRTurpieAGKakkarAKErikssonBIGentMPotential impact of rivaroxaban on surgical safety outcomes after total hip or knee replacement surgeryAnnual Meeting of the International Society on Thrombosis and Haemostasis. PP-WE-404July 2009
- KwongLMOnce-daily, oral rivaroxaban for the prevention of venous thromboembolism (VTE) after total hip or knee replacement (THR/TKR) surgeryWestern Orthopaedic Association Annual Meeting Podium presentation: PM SessionSeattle, WAAugust 1, 2009
- KwongLMBleeding and Thrombo. Poster presentation # 462011Mid- America Orthopaedic Association Annual MeetingApril 7–8, 2011
- KwongLMCost-effectiveness of rivaroxaban after total hip or knee arthroplastyAm J Manag Care201117SupplS222621517652
- KwongLMDuranADiamantopoulosASenguptaNLeesMCost- effectiveness of rivaroxaban for prevention of venous thromboemebolism (VTE) after total hip or knee replacement (THR, TKR) in the US. [Abstract]J Thromb Haemost20097Suppl 2PP-WE-473